全基因组DNA甲基化谱在非1p/19q缺失间变性胶质瘤中的预后意义:EORTC CATNON随机III期试验
基于EORTC CATNON III期试验中751例新诊断非1p/19q缺失间变性胶质瘤患者,对654例肿瘤行全基因组DNA甲基化分析和NGS,其中432例为IDH1/2突变型间变性星形细胞瘤。两种表观遗传分类器均识别出预后较差患者且部分重叠,多因素Cox模型确定年龄、MMSE评分、替莫唑胺治疗、表观遗传分类器、PDGFRA扩增、CDKN2A/B纯合缺失、PI3K突变和总CNV负荷为独立预后因素。
要点
- IDH1/2突变型间变性星形细胞瘤生存高度异质,需结合临床与分子因素分层。
- 两种DNA甲基化分类器可识别预后较差患者,结果部分重叠。
- PDGFRA扩增、CDKN2A/B纯合缺失、PI3K突变及总CNV负荷为独立预后因素。
核心结论
- 临床和分子因素均可识别IDH1/2突变型间变性星形细胞瘤中预后更差的患者,结果将进一步完善当前WHO胶质瘤分类标准。
研究设计与样本
- EORTC CATNON随机III期试验纳入751例新诊断1p/19q非共缺失间变性胶质瘤成人患者,随机接受59.4 Gy放疗联合或不联合同期和/或辅助替莫唑胺。
- 对654例肿瘤成功行全基因组DNA甲基化分析(Infinium MethylationEPIC BeadChip芯片)和NGS,其中432例为IDH1/2突变型间变性星形细胞瘤。
- 主要终点为从随机化日期起计算的总生存期。
主要发现
- 两种表观遗传分类器均识别出预后较差患者,且部分重叠。
- 多因素Cox比例风险模型确定IDH1/2突变型间变性星形细胞瘤的独立预后因素包括:年龄、简易精神状态检查评分、同期和/或辅助替莫唑胺治疗、表观遗传分类器、PDGFRA扩增、CDKN2A/B纯合缺失、PI3K突变和总CNV负荷。
- 独立递归 partitioning 分析强调上述因素对患者预后判断的重要性。
临床怎么用
- 对IDH1/2突变型间变性星形细胞瘤患者,可结合年龄、MMSE评分、替莫唑胺治疗及分子特征(表观遗传分类器、PDGFRA扩增、CDKN2A/B纯合缺失、PI3K突变、总CNV负荷)进行预后分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Survival in patients with IDH1/2-mutant (mt) anaplastic astrocytomas is highly variable. We have used the prospective phase 3 CATNON trial to identify molecular factors related to outcome in IDH1/2mt anaplastic astrocytoma patients. METHODS: The CATNON trial randomized 751 adult patients with newly diagnosed 1p/19q non-codeleted anaplastic glioma to 59.4 Gy radiotherapy +/- concurrent and/or adjuvant temozolomide. The presence of necrosis and/or microvascular proliferation was scored at central pathology review. Infinium MethylationEPIC BeadChip arrays were used for genome-wide DNA methylation analysis and the determination of copy number variations (CNV). Two DNA methylation-based tumor classifiers were used for risk stratification. Next-generation sequencing (NGS) was performed using 1 of the 2 glioma-tailored NGS panels. The primary endpoint was overall survival measured from the date of randomization. RESULTS: Full analysis (genome-wide DNA methylation and NGS) was successfully performed on 654 tumors. Of these, 432 tumors were IDH1/2mt anaplastic astrocytomas. Both epigenetic classifiers identified poor prognosis patients that partially overlapped. A predictive prognostic Cox proportional hazard model identified that independent prognostic factors for IDH1/2mt anaplastic astrocytoma patients included; age, mini-mental state examination score, treatment with concurrent and/or adjuvant temozolomide, the epigenetic classifiers, PDGFRA amplification, CDKN2A/B homozygous deletion, PI3K mutations, and total CNV load. Independent recursive partitioning analysis highlights the importance of these factors for patient prognostication. CONCLUSION: Both clinical and molecular factors identify IDH1/2mt anaplastic astrocytoma patients with worse outcome. These results will further refine the current WHO criteria for glioma classification.
引用
- Tesileanu CMS, van den Bent MJ, Sanson M, et al. Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. Neuro Oncol. 2021. PMID: 33914057. doi:10.1093/neuonc/noab088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。